Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

RIZZO, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.103
EU - Europa 2.188
AS - Asia 824
AF - Africa 32
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 10.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.090
IT - Italia 773
CN - Cina 445
FI - Finlandia 395
DE - Germania 250
SG - Singapore 230
UA - Ucraina 210
IE - Irlanda 131
GB - Regno Unito 124
RU - Federazione Russa 73
SE - Svezia 57
BE - Belgio 46
FR - Francia 45
KR - Corea 42
IN - India 36
RO - Romania 32
CI - Costa d'Avorio 30
TR - Turchia 17
IR - Iran 16
NL - Olanda 15
ES - Italia 11
CA - Canada 10
JP - Giappone 7
BR - Brasile 6
UZ - Uzbekistan 6
CH - Svizzera 5
EU - Europa 5
DK - Danimarca 4
HK - Hong Kong 4
IL - Israele 4
LB - Libano 4
PL - Polonia 4
TW - Taiwan 4
AT - Austria 3
CL - Cile 3
AU - Australia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
KZ - Kazakistan 2
MX - Messico 2
NO - Norvegia 2
PE - Perù 2
AL - Albania 1
BG - Bulgaria 1
GR - Grecia 1
HR - Croazia 1
ID - Indonesia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 10.168
Salva come PNG Salva come JPEG
Città #
Fairfield 1.351
Ashburn 680
Woodbridge 621
Chandler 530
Seattle 517
Houston 476
Wilmington 468
Cambridge 405
Ann Arbor 391
Palermo 214
Singapore 180
Dublin 129
Medford 124
Des Moines 120
Jacksonville 106
Altamura 94
Nanjing 93
Princeton 79
San Diego 77
Lawrence 71
Dearborn 66
Beijing 49
Brussels 44
Boardman 43
Ludwigshafen am Rhein 41
New York 40
Santa Clara 37
Jinan 34
Tulsa 32
Seongnam 31
Abidjan 30
Shenyang 30
Tianjin 30
Hebei 28
London 28
Nanchang 28
Bremen 26
Phoenix 26
Milan 22
Kumar 21
Changsha 20
Kitzingen 18
Helsinki 16
Izmir 16
Ningbo 16
Saint Petersburg 16
Berlin 15
Jiaxing 15
Orange 15
San Paolo di Civitate 14
Chicago 13
Tehran 13
Guangzhou 12
Kilburn 10
Los Angeles 10
Pune 10
Zhengzhou 10
Columbus 9
Fuzhou 9
Redwood City 9
Rome 9
Venice 9
Munich 8
Taiyuan 8
Verona 8
Washington 8
Kunming 6
Norwalk 6
Amsterdam 5
Atlanta 5
Aversa 5
Falls Church 5
Haikou 5
Hefei 5
Seoul 5
Taizhou 5
Tappahannock 5
Agrigento 4
Bologna 4
Cagliari 4
Edinburgh 4
Frankfurt am Main 4
Hong Kong 4
Messina 4
Shanghai 4
Toronto 4
Walnut 4
Casteltermini 3
Hanover 3
Islington 3
Madrid 3
Marano di Napoli 3
Mascalucia 3
Mountain View 3
Nürnberg 3
San Jose 3
San Mateo 3
São Paulo 3
Taipei 3
Tokyo 3
Totale 7.864
Salva come PNG Salva come JPEG
Nome #
EGFR inhibition in NSCLC: New findings…. and opened questions? 253
KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection. 194
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 192
Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin 191
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 190
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 188
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 180
A headlight on liquid biopsies: a challenging tool for breast cancer management 179
Anti-endothelin drugs in solid tumors 178
EGFR genomic alterations in cancer: prognostic and predictive values 175
HER2-positive male breast cancer: An update 170
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? 169
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 169
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 164
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 163
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 163
Nintedanib in NSCLC: Evidence to date and place in therapy 163
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 162
Co-expression of CD133+/CD44+in human colon cancer and liver metastasis 161
Monoclonal antibodies in gastrointestinal cancers 161
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 159
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 159
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 158
Breast cancer genome-wide association studies: there is strength in numbers 157
Biomarkers and efficacy: Are we nearly there yet? 157
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) 152
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 152
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 152
Gene signatures in CRC and liver metastasis 151
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 150
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 150
Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? 149
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 149
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 148
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. 147
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 145
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients 141
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 141
New molecular targets in bone metastases 139
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 139
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 139
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 139
Sex steroids, carcinogenesis, and cancer progression 139
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 134
Hereditary ovarian cancer 133
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 132
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 131
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 130
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients 129
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 125
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer 122
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 118
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 117
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 115
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting 113
Male breast cancer. 112
The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population 111
Bortezomib: a new pro-apoptotic agent in cancer treatment. 108
Could starvation minimize chemotherapy-induced toxicities? 106
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 104
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 102
PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. 100
Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients 97
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 96
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 94
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. 92
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 92
Uncoupling Protein 2 as genetic risk factor for systemic lupus erythematosus: association with malondialdehyde levels and intima media thickness 91
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy 90
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 86
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. 85
Early stage nasal vestibule tumors: safety and efficacy of HDR brachyterapy in elderly patients 84
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 83
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 73
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 72
null 69
La consulenza genetica in oncologia: implicazioni biomolecolari e cliniche. 68
"ONCOGENE ADDICTED SOLID TUMORS: BIOMARKERS PROGNOSTIC AND PREDICTIVE OF RESISTANCE OR SENSITIVITY TO MOLECULAR TARGETED THERAPIES IN CRC 52
Cardiovascular risk in patients without known cardiovascular disease 44
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 43
null 9
Totale 10.639
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.916 0 0 0 0 347 362 292 221 256 161 198 79
2020/20211.398 87 96 73 117 97 54 145 107 171 178 156 117
2021/20221.192 68 295 30 38 63 46 87 52 105 140 96 172
2022/20231.525 147 300 37 193 153 235 111 105 143 8 55 38
2023/2024632 31 84 50 42 37 114 73 78 2 15 12 94
2024/2025392 31 108 97 128 28 0 0 0 0 0 0 0
Totale 10.639